BioVie Inc.
$1.58
▲
2.9%
2026-04-21 05:40:01
bioviepharma.com
NCM: BIVI
Explore BioVie Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$11.77 M
Current Price
$1.58
52W High / Low
$13.2 / $1.06
Stock P/E
—
Book Value
$2.56
Dividend Yield
—
ROCE
-93.67%
ROE
-80.74%
Face Value
—
EPS
$-3.28
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
13
Beta
0.56
Debt / Equity
1.64
Current Ratio
7.25
Quick Ratio
9.1
Forward P/E
-0.31
Price / Sales
—
Enterprise Value
$-10.05 M
EV / EBITDA
0.56
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Reviva Pharmaceuticals Holdings, Inc. | $0.91 | — | $10.89 M | — | -233.59% | -4.2% | $23.2 / $0.59 | $1.47 |
| 2. | Cue Biopharma, Inc. | $0.85 | — | $82.97 M | — | -92.35% | -121.11% | $1.03 / $0.17 | $0.27 |
| 3. | Spruce Biosciences, Inc. | $69.89 | — | $96.45 M | — | -85.04% | -1.09% | $240 / $4.28 | $30.99 |
| 4. | Septerna, Inc. | $26.86 | — | $1.17 B | — | -15.87% | -12.19% | $32.63 / $5.73 | $8.52 |
| 5. | Gain Therapeutics, Inc. | $2.12 | — | $89.98 M | — | -96.12% | -1.56% | $4.34 / $1.41 | $0.44 |
| 6. | Ginkgo Bioworks Holdings, Inc. | $7.98 | — | $492.71 M | — | -29.68% | -51.08% | $17.58 / $5.37 | $8.74 |
| 7. | Tvardi Therapeutics, Inc. | $3.22 | — | $30.72 M | — | -127.18% | -2.38% | $43.65 / $2.75 | $2.23 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -6.26 M | -5.28 M | -3.66 M | -2.99 M | -7.29 M | — |
| Net Profit | -6.07 M | -5.09 M | -3.49 M | -2.79 M | -7.11 M | — |
| EPS in Rs | -0.8 | -0.67 | -0.46 | -0.37 | -0.94 | -7 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -18.07 M | -32.18 M | -45.08 M | -27.25 M |
| Net Profit | -17.54 M | -32.12 M | -50.26 M | -26.08 M |
| EPS in Rs | -2.33 | -4.26 | -6.66 | -3.46 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 21.56 M | 25.21 M | 35.1 M | 20.11 M |
| Total Liabilities | 2.55 M | 9.7 M | 19.76 M | 16.44 M |
| Equity | 19.01 M | 15.51 M | 15.34 M | 3.67 M |
| Current Assets | 20.7 M | 24.05 M | 34.04 M | 18.78 M |
| Current Liabilities | 2.27 M | 9.35 M | 14.49 M | 4.17 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -19.03 M | -27.95 M | -40.25 M | -18.99 M |
| Investing CF | 0 M | 14.53 M | -14.3 M | 0 M |
| Financing CF | 12.73 M | 17.8 M | 55.37 M | 33.12 M |
| Free CF | -19.03 M | -27.95 M | -40.25 M | -18.99 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 36.09% | -92.67% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-07-07 | 1:0.1 |
| 2024-08-06 | 1:0.1 |